Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 21%
Hold 50%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is positioned to see significant growth in the coming years driven by potential blockbuster drugs in its pipeline, including sotatercept, admilparant, and milvexian. The company's guidance, recent positive clinical trial results, and increased confidence in its transformative potential from experts in various therapeutic areas are key reasons for the analyst's positive outlook. With strong growth potential and a solid dividend, Bristol-Myers Squibb presents an attractive investment opportunity for investors.

Bears say

Bristol-Myers Squibb is expected to have a solid quarter due to strong sales of growth products such as Opdivo/Qvantig, Camzyos, and Reblozyl, and continued growth for Eliquis. However, upcoming clinical readouts and label expansions for key drugs like milvexian (SPAF/SSP), admilparant (IPF), and Cobenfy (ADP) may bring about a unique multiple expansion opportunity and drive further investor interest. Risks to this outlook include potential competition in rare CV, I&I and oncology markets, clinical failures, and regulatory delays.

Bristol-Myers (BMY) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 14 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.